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Background: Limited data on a short series of patients suggest that lymphocytic enteritis (classically
considered as latent coeliac disease) may produce symptoms of malabsorption, although the true
prevalence of this situation is unknown. Serological markers of coeliac disease are of little diagnostic value
in identifying these patients.
Aims: To evaluate the usefulness of human leucocyte antigen-DQ2 genotyping followed by duodenal
biopsy for the detection of gluten-sensitive enteropathy in first-degree relatives of patients with coeliac
disease and to assess the clinical relevance of lymphocytic enteritis diagnosed with this screening strategy.
Patients and methods: 221 first-degree relatives of 82 DQ2+ patients with coeliac disease were
consecutively included. Duodenal biopsy (for histological examination and tissue transglutaminase
antibody assay in culture supernatant) was carried out on all DQ2+ relatives. Clinical features,
biochemical parameters and bone mineral density were recorded.
Results: 130 relatives (58.8%) were DQ2+, showing the following histological stages: 64 (49.2%) Marsh
0; 32 (24.6%) Marsh I; 1 (0.8%) Marsh II; 13 (10.0%) Marsh III; 15.4% refused the biopsy. 49 relatives
showed gluten sensitive enteropathy, 46 with histological abnormalities and 3 with Marsh 0 but positive
tissue transglutaminase antibody in culture supernatant. Only 17 of 221 relatives had positive serological
markers. Differences in the diagnostic yield between the proposed strategy and serology were significant
(22.2% v 7.2%, p,0.001). Relatives with Marsh I and Marsh II–III were more often symptomatic (56.3%
and 53.8%, respectively) than relatives with normal mucosa (21.1%; p = 0.002). Marsh I relatives had
more severe abdominal pain (p = 0.006), severe distension (p = 0.047) and anaemia (p = 0.038) than
those with Marsh 0. The prevalence of abnormal bone mineral density was similar in relatives with Marsh I
(37%) and Marsh III (44.4%).
Conclusions: The high number of symptomatic patients with lymphocytic enteritis (Marsh I) supports the
need for a strategy based on human leucocyte antigen-DQ2 genotyping followed by duodenal biopsy in
relatives of patients with coeliac disease and modifies the current concept that villous atrophy is required to
prescribe a gluten-free diet.
A
ccording to the European Society of Paediatric
Gastroenterology and Nutrition criteria,1 intestinal
villous atrophy is a sine qua non for diagnosing coeliac
disease and only in this situation should a gluten-free diet
(GFD) be recommended. In addition, it was traditionally
considered that Marsh I infiltrative lesion (lymphocytic
enteritis) was not associated with any symptom or sign of
malabsorption.2
However, it has recently been recognised from a short
series of selected patients that gluten-sensitive enteropathy
(GSE) with preserved villous architecture may be clinically
relevant.3–6 Anti-endomysial (EmA) and tissue transglutami-
nase antibodies (t-TGA) are of little diagnostic value in
identifying patients with lymphocytic enteritis as they are
positive in only 30% of cases.7 At present, there is no reliable
evidence of how often patients with mild enteropathy have
clinical symptoms and of the severity of these symptoms.
Consequently, there are no recommendations for the
management of patients with mild enteropathy diagnosed
in screening programmes for coeliac disease.
First-degree relatives of patients with coeliac disease might
benefit from case finding through different diagnostic
strategies.8 In this sense, about 10% disease prevalence has
been found using serological methods for screening pur-
poses.9 10 In our geographical area, specific human leucocyte
antigen (HLA)-DQ2 alleles are present in .90% of patients
with coeliac disease, 60% of first-degree relatives and 20% of
the general population.10 Thus, DQ2 genotyping identifies
susceptible people in a particular risk group.11 To our
knowledge, there is no information about the usefulness of
HLA genotyping followed by duodenal biopsy in positive
cases as a diagnostic strategy of GSE in first-degree relatives
of patients with coeliac disease.
The aims of the present study were to evaluate: (1) the
usefulness of a strategy consisting of HLA genotyping
followed by duodenal histological examination and t-TGA
determinations in the culture supernatant of duodenal biopsy
specimens from DQ2+ subjects, for the diagnosis of GSE in
first-degree relatives of patients with coeliac disease and (2)
Abbreviations: BMD, bone mineral density; EmA, endomysial
antibodies; GFD, gluten-free diet; GSE, gluten-sensitive enteropathy;
HLA, human leucocyte antigen; IEL, intraepithelial lymphocytes; PCR,
polymerase chain reaction; t-TGA, tissue transglutaminase antibodies;
VAS, visual analogue scale
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the clinical relevance of lymphocytic enteritis diagnosed in
this screening programme.
MATERIALS AND METHODS
Subjects
Index cases included both previously and newly diagnosed
DQ2+ patients with coeliac disease recruited consecutively in
the outpatient clinic of the three participant hospitals
between January 2004 and June 2005. All first-degree
relatives of every index case were invited to participate in
the study, and the family was considered evaluable if at least
one first-degree relative agreed to be included. Diagnosis of
coeliac disease in index cases was based on the European
Society of Paediatric Gastroenterology and Nutrition1 and
American Gastroenterological Association criteria.12
Two hundred and seventy six first-degree relatives of 82
DQ2+ patients with coeliac disease (32 males and 50 females;
mean age 16.5 years (12 months–77 years)) were identified,
and 221 of them (80%; 109 parents, 75 siblings and 37
offspring) were finally included in the study (104 males and
117 females; mean age 34 years (22 months–72 years)) The
remaining 55 first-degree relatives (25 parents, 24 siblings
and 6 offspring) were not included for several reasons that
were recorded in order to disclose a possible selection bias.
The reasons for not participating were (1) living in a distant
place (50%), (2) being ,18 months (9%), and (3) refusal to
participate even in the presence of symptoms (41%). For 53
index cases all first-degree relatives could be studied.
Proposed diagnostic strategy and study design
After written informed consent was obtained from the
subjects or their parents, blood sampling was performed for
HLA-DQ2 genotyping and serum EmA and t-TGA assay.
Figure 1 depicts the diagnostic strategy implemented to study
first-degree relatives. Duodenal biopsy was carried out on all
DQ2+ relatives, irrespective of the results of the serum-
specific autoantibody (EmA and t-TGA) assay. t-TGA were
also determined in the culture supernatant of duodenal
biopsy specimens. First-degree relatives were considered to
have GSE if some degree of histological abnormality or a
specific humoral response (in serum or duodenal biopsy
culture) was found. The presence of anaemia, hypertrans-
aminasaemia, diarrhoea, abdominal pain, abdominal disten-
sion, flatulence and asthenia, and serum ferritin
concentration were recorded in all DQ2+ relatives. The
questionnaire of symptoms was administered to the patients
(or parents of paediatric patients). A relative was considered
symptomatic when at least one of the above-mentioned
symptoms was present. In addition, in adult relatives
(n = 67), the following symptoms were quantified by using
a visual analogue scale (VAS)13 ranging from 0 to 100:
diarrhoea, abdominal pain, abdominal distension, flatulence,
asthenia, irritability, difficulties in concentration capacity
and insomnia. A symptom was considered to be severe if it
scored .50 points.
Genetic markers
Standard techniques were used for DNA extraction, poly-
merase chain reaction (PCR) amplification and product
detection. To purify genomic DNA from whole blood, a
commercial reagent Generation Capture Column Kit (Gentra
Systems, Minneapolis, Minnesota, USA) was used. HLA-DQ2
(DQA1*0501 and DQB1*0201 alleles) genotyping was per-
formed by PCR amplification using sequence-specific pri-
mers,14 on a GeneAmp PCR 2400 System (Perkin-Elmer,
Norwalk, Connecticut, USA). PCR products were detected by
electrophoresis on a 2% agarose gel and were visualised
under ultraviolet light.
Duodenal biopsy
Four endoscopic biopsy specimens from the second and third
portions of the duodenum were processed using haematox-
ylin–eosin staining and CD3 immunophenotyping,15 and they
were blindly evaluated by an expert gastrointestinal pathol-
ogist (AS). Histopathological findings were staged according
to the Marsh criteria,16 as revised by Rostami et al 17:
‘‘infiltrative’’ lesions with intraepithelial lymphocytosis were
defined as Marsh I, ‘‘infiltrative/hyperplastic’’ lesions were
defined as Marsh II, and ‘‘partial (A), subtotal (B) and total
(C) villous atrophy’’ as Marsh III. We assumed intraepithelial
lymphocytosis to be present if .25 IEL/100 epithelial cells
were observed.18
Two additional biopsy specimens of the same area were
kept for 48 h at 37 C˚ in culture medium (Bio-MPM-1 Multi –
purpose SFM for adherent cells (Biological Industries Ltd,
Kibbutz Beit Haemek, Israel), antibiotic (100 000 U/ml) and
L-glutamine (2 mM)) for t-TGA assay in culture supernatant
by using a modification of the method described by Picarelli
et al19 (see below). Culture supernatants were collected and
stored at 270 C˚ until analysis.
Antibody detection
Serum IgA–EmA was determined by indirect immunofluor-
escence assay in serum samples at 1:5 dilution, as described
previously.20 Commercial sections of monkey distal oesopha-
gus (BioMedical Diagnostics, Marne-la-Valle´e, France) were
used as indirect immunofluorescence substrate.
Figure 1 Proposed diagnostic strategy. CSDB, culture supernatant of
duodenal biopsy; EmA, endomysial antibodies; HLA, human leucocyte
antigen; t-TGA, tissue transglutaminase antibodies.
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IgA-class t-TGA were analysed in the serum and culture
supernatant of duodenal biopsy specimens using a quantita-
tive and automated ELISA method by means of a commer-
cially available detection kit (Celikey, Sweden Diagnostics
GmbH, Freiburg, Germany) using recombinant human tissue
transglutaminase as antigen.21 In serum, values .8 U/ml
were considered positive, as established by the manufacturer.
In culture supernatant, the cut-off value in our laboratory
was established by assessing 330 samples of people belonging
to risk populations (those with anaemia, first-degree
relatives, those with type I diabetes, etc). The IgA-class t-
TGA concentration in culture supernatant (1:20 diluted) was
analysed using the same calibration curve as in the serum
samples (1:100 diluted, as recommended by the manufac-
turer). Thus, U/ml in culture supernatant were in fact U/ml:5.
Results .0.6 U/ml in culture supernatant were considered
positive (intra-assay and interassay variability were 5.05 and
8.37, respectively). In the above-mentioned risk population,
t-TGA in culture supernatant of duodenal biopsy specimens
was positive in 2% Marsh 0, 20.5% Marsh I and 92.4% Marsh
III (M Esteve, personal communication, 2005).
Total serum IgA was measured using rate nephelometry
(BN II, Dade Behring, Frankfurt, Germany). In cases of IgA
deficiency, IgG-class EmA was determined.
Measurement of bone mineral density
Bone mineral density (BMD) was assessed in all DQ2+
relatives having some degree of histological abnormality
(Marsh I–III), and in all newly diagnosed cases of coeliac
disease (Marsh III), before starting a GFD, recruited in one of
the three participant hospitals (Hospital Mu´tua de Terrassa,
Fundacio´ per la Recerca Mu´tua de Terrassa, Universitat de
Barcelona, Terrassa, Catalonia, Spain). BMD was evaluated in
18 patients with Marsh III (12 index cases and 6 relatives; 2
males, 16 females; mean age 35.3 (range 23–77)) and in 26
relatives with Marsh I (11 males, 15 females; mean age
37.1 years (range 12–66)). The t and z scores were measured
in lumbar spine and left femoral neck using dual-energy
x ray absorptiometry (Lunar DPX-aph, General Electric,
Milwaukee, Wisconsin, USA). Osteopenia was defined as a
value of BMD .1 SD below the average value of a young
adult, but not .2.5 SD below (t score 21 to 22.5). According
to World Health Organization criteria, osteoporosis was
defined as a value of BMD .2.5 SD below the average value
of a young adult (t score ,22.5).22 Comparisons were made
to assess differences between people with atrophy (both pat-
ients and relatives) and relatives with lymphocytic enteritis.
Statistical analysis
Qualitative parameters were expressed as proportions,
whereas quantitative variables were expressed as either mean
and standard error of the mean (SEM) or median and range.
x2 statistics and Fisher’s exact test were used to assess
considerable associations between qualitative variables.
McNemar’s test was used to compare paired proportions.
One-way ANOVA and Student’s t test were used to compare
quantitative variables. A p value ,0.05 was considered to be
significant. All statistical calculations were performed using
the SPSS for Windows Statistical package.
RESULTS
Prevalence and histological severity of GSE in first-
degree relatives of patients with coeliac disease
Of the 221 first-degree relatives, 130 (58.8%) were DQ2+. In
all, 20 (15.4%) DQ2+ relatives with negative serum EmA and
t-TGA refused the biopsy. Duodenal biopsy was performed in
110 relatives having the following histological stages: 64
(49.2%) Marsh 0, 32 (24.6%) Marsh I, 1 (0.8%) Marsh II and
13 (10%) Marsh III. The median number of IEL of relatives
with Marsh I lesion was 39% (limits 27–70). Thus,
histological abnormalities were found in 46 of 110 relatives
who underwent biopsy (41.8%). Figures 2 and 3 provide a
detailed description of the histological findings. Table 1
shows the sex and age distribution and the family relation-
ship with the index cases of all DQ2 relatives.
As mentioned previously, for 53 of 82 index cases all family
members (89 relatives) could be assessed. Histological
findings in these relatives were as follows: 48 (53.9%)
Marsh 0, 23 (24.7%) Marsh I, 7 (8.9%) Marsh II–III and 11
(12.4%) did not accept the biopsy. The extent of biopsy
acceptance was similar in families totally or partially
evaluated (87.7% v 85.6%; p = 0.193). There were no
significant differences in the degree of histological severity
between relatives of families in whom all first-degree
relatives could or could not be evaluated (p = 0.132).
Relatives with the most severe intestinal damage usually
belonged to the same generation as the index case, whereas
lymphocytic enteritis was more often found in the parents’
generation (fig 2). Consequently, relatives with the most
severe lesions (Marsh II–III) were significantly younger
(mean (SD) age 24.1(3.7) years) than patients with lympho-
cytic enteritis (Marsh I; mean (SD) age 32.9 (2.3) years;
Student’s t test, p = 0.044). A non-significant predominance
of more severe lesions was observed in females (females:
50.0% Marsh 0, 31.7% Marsh I, 18.3% Marsh II–III; males:
65.3% Marsh 0, 28.6% Marsh I, 6.1% Marsh II–III; x2 test,
p = 0.115).
Diagnostic performance of serology as compared with
the present diagnostic strategy
Of the 221 relatives, 16 (7.2%) had positive serological
markers (both EmA and t-TGA). The histological spectrum of
these patients was as follows: 5 Marsh I, 2 Marsh IIIA, 7
Marsh IIIB and 2 Marsh IIIC. Three relatives with Marsh II,
Marsh IIIA and Marsh IIIB, 27 relatives with Marsh I and 64
with Marsh 0 had negative serological markers. The
sensitivity of serology for Marsh I and Marsh III detection
was 15.6% and 84.6%, respectively.
Of the 221 relatives, 23 (10.5%) had positive t-TGA in the
culture supernatant of duodenal biopsy—the 16 relatives
with positive serological markers and the other 7 who were
negative for serum antibodies (4 Marsh I and 3 Marsh 0). The
sensitivity of t-TGA in the culture supernatant in the
different histological degrees of GSE was 4.6%, 28.1% and
84.6% in Marsh 0, Marsh I and Marsh III, respectively.
Thus, using the current diagnostic strategy, 49 of 221
relatives (22.2%) showed several degrees of GSE (46 with
n = 2
33 parents (51.6%)
22 siblings (34.4%)
9 offspring (14.1%)
n = 8
n = 3n = 1
n = 32
n = 64
19 parents (59.4%)
11 siblings (34.4%)
2 offspring (6.3%)
5 parents (35.7%)
8 siblings (57.1%)
1 offspring (7.1%)
50
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Figure 2 Family relationship in different degrees of histological
severity.
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histological abnormalities and 3 with normal mucosa but
positive t-TGA in culture supernatant; fig 3). The difference
between the current diagnostic strategy and the standard
screening by serology was significant (22.2% v 7.2%,
McNemar’s test, p,0.001).
Clinical manifestations of GSE in first-degree relatives
Table 2 shows the frequencies of the symptoms related to the
degree of histological severity. Relatives with Marsh I and
Marsh II–III lesions were significantly more often sympto-
matic (56.3% and 53.8%, respectively) than patients with
normal mucosa (21.1%; Marsh 0; x2 test; p = 0.002).
Flatulence, distension and asthenia were significantly more
frequent in Marsh I and II–III than in Marsh 0 (p = 0.019,
0.003 and 0.002, respectively). Similar results were obtained
when symptoms were assessed only in adult patients, by
means of a VAS (table 3). Except for insomnia and
difficulties in concentration capacity, a progressive increase
in the mean values of the VAS was observed from Marsh 0 to
Marsh III (table 3). A significant difference was found for
abdominal pain (p = 0.026), distension (p = 0.031) and
asthenia (p = 0.010).
Table 4 shows the frequency of severe symptoms
(VAS.50) related to the degree of mucosal lesion. Relatives
with Marsh I lesion had more severe abdominal pain
(p = 0.006) and more severe distension (p = 0.047) than
relatives with normal mucosa (Marsh 0; Fisher’s exact test).
Similarly, relatives with Marsh II–III lesion had more severe
abdominal pain (p = 0.005), more severe distension
(p = 0.024) and asthenia (p = 0.024) than relatives with
normal mucosa (Marsh 0; Fisher’s exact test).
In all, 4 (6.2%) relatives with Marsh 0, 7 (21.8%) with
Marsh I and 3 (21.4%) with Marsh II–III had anaemia. There
was a significant difference between Marsh 0 and Marsh I
(p = 0.038; Fisher’s exact test) and a similar, but not
significant trend between Marsh 0 and Marsh II–III
(p = 0.104; Fisher’s exact test). Moreover, two of the four
relatives with Marsh 0 and anaemia had positive t-TGA
(values of 28 and 0.8 U/ml) in culture supernatant of
duodenal biopsy specimens. Overall most relatives had
normal plasma ferritin concentration. However, a progressive
decrease from Marsh 0 to Marsh III was observed (mean
(SEM): Marsh 0, 127.5 (22.2) ng/ml; Marsh I, 84.07
(21.27) ng/ml; Marsh II–III, 58.9 (19.26) ng/ml; p = 0.059).
Similarly, 1 (1.5%) relative with Marsh 0, 3 (9.3%) with
Marsh I and 1 (7.1%) with Marsh II–III had hypertrans-
aminasaemia. Differences between Marsh 0 and Marsh I and
between Marsh 0 and Marsh II–III were not significant
(p = 0.113 and 0.326, respectively; Fisher’s exact test)
Comparison of BMD between patients with
lymphocytic enterit is (Marsh I) and those with vil lous
atrophy (Marsh III)
Osteoporosis was diagnosed in only one relative (woman,
72 years) having atrophy (Marsh IIIb). Osteopenia was
found in 10 patients with lymphocytic enteritis (37.0%) and
in 7 patients with atrophy (38.8%). Taking osteopenia and
osteoporosis as a whole, there were no significant differences
in the percentage of abnormal BMD between patients with
Marsh I (37.0%) and those with Marsh III (44.4%; x2 test,
p = 0.761). There were also no significant differences in mean
t and z scores (table 5). There was no significant difference
between the age of patients with lymphocytic enteritis (mean
(SEM) age: 37.1 (2.1) years) and those with atrophy (mean
(SEM) age: 35.3 (2.8) years; Student’s t test, p = 0.615),
whereas a female predominance was found in patients with
atrophy (84.6 v 48.4%; x2 test: p = 0.043).
DISCUSSION
It is accepted that first-degree relatives of patients with coel-
iac disease may benefit from screening programmes23 24 and it
is also known that serologic testing (t-TG and EmA) misses a
subgroup of patients, particularly those with partial villous
atrophy or lymphocytic enteritis.7 25 As HLA-DQ2 status is the
strongest determinant for coeliac autoimmunity,11 we have
Figure 3 Exploring the coeliac iceberg using the new diagnostic
strategy: differences in the diagnostic yield between the proposed
diagnostic strategy and standard screening by serology. CSDB, culture
supernatant of duodenal biopsy; EmA, endomysial antibodies; GSE,
gluten-sensitive enteropathy; t-TGA, tissue transglutaminase.
Table 1 Sex and age distribution and family relationship
between the DQ2+ relatives, relatives who underwent
biopsy and relatives with abnormal biopsy
Family relationship
(%)
Sex distribution
(%)
Age (median
and range)
DQ2+
relatives
(n = 130)
65 parents (50.0) 56 males (43.1) 35.0 years
(22 months–68 years)
49 siblings (37.7) 74 females (56.9)
16 offspring (12.3)
Relatives
who
underwent
biopsy
(n = 110)
57 parents (51.8) 49 males (44.5) 34.5 years
(22 months–68 years)
41 siblings (37.3) 61 females (55.5)
12 offspring (10.9)
Relatives
with
abnormal
biopsy
(n = 46)
24 parents (52.2) 17 males (36.9) 34.0 years
(22 months–56 years)
19 siblings (41.3) 29 females (63.1)
3 offspring (6.5)
Table 2 Frequencies of the symptoms related to the
degree of histological severity
Normal
mucosa
(Marsh 0)
n = 64 (%)
Lymphocytic
enteritis
(Marsh I)
n = 32 (%)
Architectural
distortion
(Marsh II–III)
n = 14 (%) p Value
Abdominal
pain
15 (23.4) 13 (40.6) 5 (38.5) 0.196
Diarrhoea 14 (21.8) 13 (40.6) 5 (38.5) 0.136
Flatulence 25 (39.0) 22 (68.8) 8 (57.1) 0.019
Distension 14 (21.8) 18 (56.3) 6 (57.1) 0.003
Asthenia 10 (15.6) 15 (46.9) 6 (46.2) 0.002
Statistical comparisons were done by the x2 test.
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used this genetic marker to identify those first-degree
relatives of DQ2+ patients who would benefit from histolo-
gical study. In addition, the presence of specific autoanti-
bodies in culture supernatant of duodenal biopsy specimens
was also analysed, on the basis of previous observations
showing that EmA detection in these samples may be useful
for diagnosing coeliac disease.26 27 Using this diagnostic
approach, we have found that 22.2% of first-degree relatives
had some evidence of GSE, most of them showing an
abnormal histological pattern. This figure is in contrast with
the 7.2% that would have been identified using serologic tests
alone. It is important to note that the percentage of DQ2+
relatives in the present study (58.8%) was in agreement with
those in previous studies.10 11
The prevalence of coeliac disease diagnosed by means of
serum antibody assay in first-degree relatives varied between
2.8%28 and 17.2%29 in different series. Factors accounting for
such a high variability have been recently reviewed,30
selection bias (inclusion of families with multiple affected
members) probably being the most important one. In the
present study, efforts were made to enrol all family members
of consecutive adult and paediatric patients with coeliac
disease attending the outpatient clinics of the three partici-
pant hospitals. The 7.2% prevalence of coeliac disease found
in this study using serological testing fits well with previous
data from our geographical area.10 However, the present
diagnostic strategy allowed us to identify the whole spectrum
of GSE, including not only patients with atrophy but also
patients with lymphocytic enteritis. To our knowledge, this is
the first report on the prevalence of lymphocytic enteritis in a
particular risk group by using the described diagnostic
strategy. In this sense, the 22.2% of cases found in this
group provides a reliable estimate of GSE in first-degree
relatives of patients with coeliac disease. This concept is
further supported by the finding of a similar degree of
histological severity in families that were totally or only
partially evaluated.
In contrast with previous studies in which in vitro EmA
production was analysed,19 26 27 we have used t-TGA (with
similar sensitivity and specificity in serum samples)25 owing
to better reproducibility of the ELISA assay. In fact, results
identical to those previously reported with EmA were found
in patients with atrophy, with 100% positive t-TGA in culture
supernatant in patients with positive t-TGA in serum. The
assessment of t-TGA in culture supernatant of duodenal
biopsy specimens did not significantly increase the diagnostic
yield of histological analysis for GSE diagnosis. Only three
cases with Marsh 0 and positive t-TGA in culture supernatant
were detected. However, two of them had unexplained
ferropenic anaemia. Regarding t-TGA positivity in patients
with Marsh I, four patients additional to those with positive
t-TGA in serum had positive t-TGA in culture supernatant,
yielding a 28.1% sensitivity of this assay for lymphocytic
enteritis. These are the first data reported in an unselected
population of first-degree relatives of patients with coeliac
disease. In a previous report, 9 of 12 patients with
lymphocytic enteritis and very high lymphocyte count (54–
78/100 epithelial cells) had positive EmA in culture super-
natant.27 Further studies should clarify whether the assess-
ment of t-TGA in culture supernatant of duodenal biopsy
specimens may be a marker for future progression of the
disease, identifying those people deserving a closer follow-up.
Recent prospective longitudinal studies9 31 suggest that the
progression from lymphocytic enteritis to atrophy would
occur in only a small percentage of patients with GSE. In our
study, relatives with mild enteropathy were significantly
older than patients with atrophy, also supporting this view.
Moreover, this finding suggests that most patients with
lymphocytic enteritis will probably remain in this phase for a
long time, probably representing the most frequent stage of
GSE in adults.
In contrast with the previous concept that this type of mild
GSE does not produce symptoms,2 a similar percentage of
both Marsh I and Marsh III relatives were symptomatic as
compared with relatives with normal mucosa. It is important
to realise that, in the present study, relatives with lympho-
cytic enteritis were diagnosed by screening and not from
symptoms, thus providing the real frequency, not previously
reported, of patients with symptoms in this particular group.
Table 3 Relationship between the values of visual
analogue scale and degree of histological severity
Normal
mucosa
(Marsh 0)
n = 32
Lymphocytic
enteritis
(Marsh I)
n = 27
Architectural
distortion
(Marsh II–III)
n = 8 p Value
Abdominal
pain
18.7 (3.0)
(0–47)
21.1 (5.6)
(0–90)
34.7 (15.7)
(0–100)
0.026
Diarrhoea 14.3 (4.3)
(0–80)
23.7 (5.3)
(0–80)
31.1 (13.5)
(0–94)
0.283
Flatulence 37.6 (5.5)
(0–90)
42.8 (5.6)
(0–100)
46.8 (10.9)
(10–90)
0.498
Distension 22.0 (5.6)
(0–90)
36.7 (6.5)
(0–90)
48.2 (12.8)
(0–100)
0.039
Asthenia 15.4 (4.9)
(0–80)
31.6 (6.5)
(0–100)
52.2 (13.8)
(0–100)
0.010
Irritability 18.2 (5.4)
(0–100)
27.9 (5.8)
(0–100)
44.4 (10.5)
(0–100)
0.123
Insomnia 22.8 (5.8)
(0–100)
22.9 (5.6)
(0–100)
37.5 (12.0)
(0–75)
0.443
Difficulties in
concentration
capacity
23.8 (5.7)
(0–100)
27.4 (6.0)
(0–100)
23.7 (12.4)
(0–90)
0.956
Statistical comparisons were done by one-way ANOVA. Results are
expressed as mean (SEM) and range.
Table 4 Frequency of severe symptoms (VAS.50) in different degrees of mucosal lesion
Normal mucosa
(Marsh 0) n = 32 (%)
Lymphocytic enteritis
(Marsh I) n = 27 (%) p Value*
Architectural distortion
(Marsh II–III) n = 8 (%) p Value
Abdominal pain 0 (0.0) 6 (22.2) 0.006 3 (37.5) 0.005
Diarrhoea 3 (9.3) 5 (18.5) 0.449 3 (37.5) 0.081
Flatulence 11 (33.4) 12 (44.4) 0.592 5 (62.5) 0.229
Distension 6 (18.7) 12 (44.4) 0.047 5 (62.5) 0.024
Asthenia 6 (18.7) 8 (29.6) 0.370 5 (62.5) 0.024
Irritability 6 (18.7) 8 (29.6) 0.370 2 (25.0) 0.649
Insomnia 6 (18.7) 5 (18.5) 1.0 3 (37.5) 0.347
Difficulties in concentration
capacity
9 (28.1) 7 (25.9) 1.0 2 (25.0) 1.0
VAS, visual analogue scale.
*Statistical comparisons between normal mucosa and lymphocytic enteritis were done by Fisher’s exact test. Statistical comparisons between normal mucosa and
architectural distortion were done by Fisher’s exact test.
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Abdominal distension and asthenia were the symptoms more
consistently associated with GSE, irrespective of the severity of
histological lesions. In contrast, insomnia and difficulties in
concentration capacity were as frequent in relatives with GSE as
in those with normal mucosa, probably indicating that both of
these conditions are highly prevalent in the general population
and lack discriminant capacity. Interestingly, a progressive
increase was found in VAS values related to the progressive
impairment of intestinal mucosa. A similar finding was
observed for ferritin concentration, suggesting a progressive
derangement in nutrient absorption from Marsh I to Marsh III
intestinal damage. Nevertheless, similar percentages of anae-
mia, hypertransaminasaemia and osteopenia were found in
patients with Marsh I as compared with those with Marsh III.
As a high percentage of patients with Marsh I were
symptomatic, it could be considered that at least these
patients might benefit from a GFD. The poorer adherence to a
GFD in patients diagnosed from a screening programme as
compared with those diagnosed on the basis of symptoms
has been argued against case finding in established risk
groups or mass-screening programmes.32 However, compli-
ance with a GFD is probably related to the severity of
symptoms33 and, in this sense, a considerably higher
proportion of relatives with lymphocytic enteritis than those
with normal mucosa had severe abdominal pain and severe
distension. The long-term benefit, if any, of preventing
complications such as osteoporosis, autoimmune disorders
or lymphoma in patients with lymphocytic enteritis is
unknown. However, it seems reasonable to advise a GFD at
least to those relatives with severe symptoms, loss of bone
mass and haematological or biochemical disturbances. It is
important to take into account that most of these patients
would not have been diagnosed by serology alone. In fact, the
need for other diagnostic strategies to improve the detection
rate of serology in relatives has been emphasised previously.34
In conclusion, the results of this study modify the current
concept of symptomatic GSE and GSE requiring a GFD. In
addition, a diagnostic strategy based on HLA-DQ2 genotyping
followed by duodenal biopsy in positive relatives seems
reasonable, at least in those with symptoms, irrespective of
the results of serologic tests.
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